Table 3. Non-haematologic toxicity.
| EC-Doc | FEC120 | |
|---|---|---|
| n=684 | n=674 | |
|
Any non-haematologic event | ||
| Grade 1–2 | 432 (63.2) | 520 (77.2) |
| Grade 3–4 | 247 (36.1) | 145 (21.5) |
|
Elevated bilirubin levels | ||
| Grade 1–2 | 0 (0.0) | 0 (0.0) |
| Grade 3–4 | 8 (1.2) | 1 (0.1) |
|
Elevated transaminase levels | ||
| Grade 1–2 | 0 (0.0) | 0 (0.0) |
| Grade 3–4 | 6 (0.9) | 10 (1.5) |
|
Nausea | ||
| Grade 1–2 | 3 (0.4) | 6 (0.9) |
| Grade 3–4 | 8 (1.2) | 11 (1.6) |
|
Vomiting | ||
| Grade 1–2 | 0 (0.0) | 0 (0.0) |
| Grade 3–4 | 24 (3.5) | 12 (1.8) |
|
Diarrhoea | ||
| Grade 1–2 | 0 (0.0) | 0 (0.0) |
| Grade 3–4 | 7 (1.0) | 12 (1.8) |
|
Alopecia | ||
| Grade 1–2 | 149 (21.8) | 252 (37.4) |
| Grade 3–4 | 4 (0.6) | 1 (0.1) |
|
Cardiac toxicity | ||
| Grade 1–2 | 1 (0.1) | 0 (0.0) |
| Grade 3–4 | 1 (0.1) | 4 (0.6) |
|
Oedema | ||
| Grade 1–2 | 12 (1.8) | 8 (1.2) |
| Grade 3–4 | 10 (1.5) | 1 (0.1) |
|
Neurological symptoms | ||
| Grade 1–2 | 8 (1.2) | 3 (0.4) |
| Grade 3–4 | 5 (0.7) | 1 (0.1) |
|
Pain | ||
| Grade 1–2 | 39 (5.7) | 31 (4.6) |
| Grade 3–4 | 35 (5.1) | 14 (2.1) |
|
Skin reactions | ||
| Grade 1–2 | 17 (2.5) | 8 (1.2) |
| Grade 3–4 | 23 (33.6) | 6 (0.9) |
|
Allergic reactions | ||
| Grade 1–2 | 0 (0.0) | 0 (0.0) |
| Grade 3–4 | 1 (0.1) | 0 (0.0) |
|
Fever | ||
| Grade 1–2 | 17 (2.5) | 48 (7.1) |
| Grade 3–4 | 6 (0.9) | 5 (0.7) |
|
Arthralgia/myalgia | ||
| Grade 1–2 | 63 (9.2) | 18 (2.7) |
| Grade 3–4 | 57 (8.3) | 8 (1.2) |
|
Mucositis | ||
| Grade 1–2 | 123 (18.0) | 146 (21.7) |
| Grade 3–4 | 52 (7.6) | 59 (8.8) |
Abbreviations: EC-Doc=epirubicin/cyclophosphamide followed by docetaxel; FEC=fluorouracil/epirubicin/cyclophosphamide.